Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX™ 2-73
September 05 2017 - 7:00AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”)
(Nasdaq:AVXL) today announced that the United States Patent and
Trademark Office has issued U.S. Patent Number 9,750,746 entitled
“ANAVEX 2-73 and certain anticholinesterase inhibitors composition
and method for neuroprotection.“ This patent provides the Company
with intellectual property protection covering composition of
matter for ANAVEX™ 2-73 directed to a novel and synergistic
neuroprotective compound combined with donepezil. The issued
patent offers protection through 2033.
“This newly issued patent expands the proprietary position of
ANAVEX™ 2-73,” said Christopher U. Missling, PhD, President and
Chief Executive Officer of Anavex. “This new patent is a
continuation of Anavex’s vigorous pursuit of intellectual property
protection for our neuroprotective therapeutics and we look forward
to continued progress, including advancing ANAVEX™ 2-73 in clinical
studies this year.“
ANAVEX™ 2-73 is an orally available, small-molecule activator of
the sigma-1 receptor which, data suggest, is pivotal to restoring
neural cell homeostasis and promoting neuroplasticity.1
Donepezil is currently the leading compound for the treatment of
Alzheimer’s disease in more than 50 countries and is postulated to
exert a therapeutic effect by enhancing cholinergic function.
ANAVEX™ 2-73 is to advance this year into a Phase 2/3 clinical
trial for the treatment of Alzheimer’s disease, as well as other
neurodegenerative and neurodevelopmental CNS indications, including
the orphan designation Rett syndrome.
1 Advances in Experimental Medicine and Biology Volume 964 2017
Sigma Receptors: Their Role in Disease and as Therapeutic
Targets
About Alzheimer’s disease
Alzheimer's disease is a progressive,
irreversible neurological disease and the most common cause of
dementia. In the U.S., there are over five million individuals
living with Alzheimer's disease and an estimated 50 million people
live with dementia worldwide. Today, there are no commercially
available therapies to address the underlying cause of Alzheimer's.
According to the World Alzheimer Report 2016, the global cost of
dementia was $818 billion in 2015 and is expected to become a
trillion-dollar disease by 2018.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, other central nervous system (CNS) diseases,
pain and various types of cancer. Anavex’s lead drug candidate,
ANAVEX™ 2-73, recently completed successfully a Phase 2a clinical
trial for Alzheimer’s disease. ANAVEX™ 2-73 is an orally available
drug candidate that restores cellular homeostasis by targeting
sigma-1 and muscarinic receptors. Preclinical studies demonstrated
its potential to halt and/or reverse the course of Alzheimer’s
disease. It has also exhibited anticonvulsant, anti-amnesic,
neuroprotective and anti-depressant properties in animal models,
indicating its potential to treat additional CNS disorders,
including epilepsy. The Michael J. Fox Foundation for Parkinson’s
Research has awarded Anavex a research grant to develop ANAVEX™
2-73 for the treatment of Parkinson’s disease to fully fund a
preclinical study, which could justify moving ANAVEXTM 2-73 into a
Parkinson’s disease clinical trial. ANAVEX™ 3-71, also targeting
sigma-1 and M1 muscarinic receptors, is a promising preclinical
drug candidate demonstrating disease modifications against the
major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including
cognitive deficits, amyloid and tau pathologies, and also with
beneficial effects on neuroinflammation and mitochondrial
dysfunctions. Further information is available at www.anavex.com.
You can also connect with the company on Twitter, Facebook and
LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors & Media:
Clayton Robertson
The Trout Group
(646) 378-2900
crobertson@troutgroup.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2023 to Sep 2024